GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Short Interest

Syntara (ASX:SNT) Short Interest


View and export this data going back to 2003. Start your Free Trial

What is Syntara Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Syntara's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syntara's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's Short Interest distribution charts can be found below:

* The bar in red indicates where Syntara's Short Interest falls into.


Syntara Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Short Interest
Comparable Companies
ASX:VIT ASX:IDT ASX:MVP ASX:LGP ASX:ECS ASX:NXS ASX:CAN ASX:RGT ASX:IVX ASX:LV1 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XTAE:TEVA XSWX:SDZ NBIX NSE:DIVISLAB
Traded in Other Exchanges
UUDA:Germany
Address
20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086
Website
https://www.syntaratx.com.au
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.